PMID- 29081091
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1976-9148 (Print)
IS  - 2005-4483 (Electronic)
IS  - 1976-9148 (Linking)
VI  - 25
IP  - 6
DP  - 2017 Nov 1
TI  - Rifampicin Alleviates Atopic Dermatitis-Like Response in vivo and in vitro.
PG  - 634-640
LID - 10.4062/biomolther.2017.147 [doi]
AB  - Atopic dermatitis (AD) is a common inflammatory skin disorder mediated by 
      inflammatory cells, such as macrophages and mast cells. Rifampicin is mainly used 
      for the treatment of tuberculosis. Recently, it was reported that rifampicin has 
      anti-inflammatory and immune-suppressive activities. In this study, we 
      investigated the effect of rifampicin on atopic dermatitis in vivo and in vitro. 
      AD was induced by treatment with 2, 4-dinitrochlorobenzene (DNCB) in NC/Nga mice. 
      A subset of mice was then treated with rifampicin by oral administration. The 
      severity score and scratching behavior were alleviated in the rifampicin-treated 
      group. Serum immunoglobulin E (IgE) and interleukin-4 (IL-4) levels were also 
      ameliorated in mice treated with rifampicin. We next examined whether rifampicin 
      has anti-atopic activity via suppression of mast cell activation. Rifampicin 
      suppressed the release of beta-hexosaminidase and histamine from human mast cell 
      (HMC)-1 cultures stimulated with compound 48/80. Treatment with rifampicin also 
      inhibited secretion of inflammatory mediators, such tumor necrosis factor-alpha 
      (TNF-alpha) and prostaglandin D(2) (PGD(2)), in mast cells activated by compound 48/80. 
      The mRNA expression of cyclooxygenase 2 (COX-2) was reduced in the cells treated 
      with rifampicin in a concentration-dependent manner. These results suggest that 
      rifampicin can be used to treat atopic dermatitis.
FAU - Kim, Seung Hyun
AU  - Kim SH
AD  - Institute of Chronic Disease and College of Pharmacy, Sahmyook University, Seoul 
      01795, Republic of Korea.
FAU - Lee, Ki Man
AU  - Lee KM
AD  - Institute of Chronic Disease and College of Pharmacy, Sahmyook University, Seoul 
      01795, Republic of Korea.
FAU - Lee, Geum Seon
AU  - Lee GS
AD  - Institute of Chronic Disease and College of Pharmacy, Sahmyook University, Seoul 
      01795, Republic of Korea.
FAU - Seong, Ju-Won
AU  - Seong JW
AD  - Institute of Chronic Disease and College of Pharmacy, Sahmyook University, Seoul 
      01795, Republic of Korea.
FAU - Kang, Tae Jin
AU  - Kang TJ
AD  - Institute of Chronic Disease and College of Pharmacy, Sahmyook University, Seoul 
      01795, Republic of Korea.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Biomol Ther (Seoul)
JT  - Biomolecules & therapeutics
JID - 101472832
PMC - PMC5685433
OTO - NOTNLM
OT  - Atopic dermatitis
OT  - Mast cell
OT  - NC/Nga mice
OT  - Rifampicin
EDAT- 2017/10/31 06:00
MHDA- 2017/10/31 06:01
PMCR- 2017/11/01
CRDT- 2017/10/31 06:00
PHST- 2017/07/18 00:00 [received]
PHST- 2017/08/11 00:00 [revised]
PHST- 2017/08/11 00:00 [accepted]
PHST- 2017/10/31 06:00 [entrez]
PHST- 2017/10/31 06:00 [pubmed]
PHST- 2017/10/31 06:01 [medline]
PHST- 2017/11/01 00:00 [pmc-release]
AID - biomolther.2017.147 [pii]
AID - bt-25-634 [pii]
AID - 10.4062/biomolther.2017.147 [doi]
PST - ppublish
SO  - Biomol Ther (Seoul). 2017 Nov 1;25(6):634-640. doi: 10.4062/biomolther.2017.147.